{
  "pmcid": "9543254",
  "sha256": "ba2c549048a125741aec46df9b473bc6fad69fbf986fd077f1a99927ade5a7d4",
  "timestamp_utc": "2025-11-09T23:01:28.344342+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.643247863247865,
    "reading_ease": 13.232307692307728,
    "word_count": 234
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Angiotensin-2 vs. Noradrenaline in Cardiac Surgery"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This double-blind, randomised feasibility trial was conducted at two metropolitan hospitals in Melbourne, Australia."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults at elevated risk of AKI undergoing cardiac surgery."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly allocated to receive either angiotensin-2 or noradrenaline"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the feasibility of using angiotensin-2 compared to noradrenaline to maintain peri-operative blood pressure."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was feasibility, assessed by consent rate, protocol adherence, infusion duration, MAP maintenance, and major adverse outcomes."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment via a REDCap database."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included participants, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Sixty participants were randomised (28 to angiotensin-2, 32 to noradrenaline) between March and September 2021."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Analysis was intention-to-treat."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "AKI occurred in 25% of the angiotensin-2 group and 38% of the noradrenaline group (p=0.31)."
      },
      "Harms": {
        "score": 1,
        "evidence": "One stroke, one extracorporeal support, and three renal replacement therapies occurred in the noradrenaline group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Australian and New Zealand Clinical Trials Registry."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}